Lafutidine

Lafutidine

Lafutidine is a type of histamine H2 receptor antagonist that is primarily used in the treatment of gastrointestinal disorders. It was first developed in Japan and is marketed under the brand name Stogar.

Pharmacology

Lafutidine works by blocking the action of histamine on the H2 receptors of the parietal cells in the stomach. This reduces the production of gastric acid, which can help to alleviate symptoms associated with conditions such as peptic ulcers and gastroesophageal reflux disease (GERD).

In addition to its H2 receptor antagonist properties, Lafutidine also has a unique mechanism of action. It stimulates the release of calcitonin gene-related peptide (CGRP), which enhances mucosal defense mechanisms in the stomach. This dual action makes Lafutidine particularly effective in the treatment of gastrointestinal disorders.

Clinical Use

Lafutidine is used in the treatment of a variety of gastrointestinal disorders, including peptic ulcers, gastroesophageal reflux disease (GERD), and gastritis. It is also used to prevent gastric ulcers in patients who are taking nonsteroidal anti-inflammatory drugs (NSAIDs).

Side Effects

Like all medications, Lafutidine can cause side effects. These may include dizziness, headache, nausea, and diarrhea. However, these side effects are generally mild and go away on their own as the body adjusts to the medication.

See Also

• Histamine H2 receptor antagonist
• Gastrointestinal disorders
• Peptic ulcers
• Gastroesophageal reflux disease
• Gastritis

‎

‎